Brokerages Set Affimed (NASDAQ:AFMD) Target Price at $16.00

Affimed (NASDAQ:AFMD) has been given a consensus rating of “Moderate Buy” by the five research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $16.00.

Several research firms recently commented on AFMD. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Stifel Nicolaus lowered their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Friday, November 15th.

Affimed Price Performance

NASDAQ:AFMD opened at $2.84 on Friday. Affimed has a 52 week low of $2.61 and a 52 week high of $8.95. The firm’s fifty day moving average is $3.31 and its 200-day moving average is $4.38. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last issued its quarterly earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). Affimed had a negative return on equity of 193.84% and a negative net margin of 7,836.26%. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.67 million. On average, equities analysts forecast that Affimed will post -4 earnings per share for the current year.

Hedge Funds Weigh In On Affimed

A number of institutional investors have recently modified their holdings of AFMD. Choreo LLC bought a new stake in Affimed during the 2nd quarter valued at $54,000. Intellectus Partners LLC increased its position in shares of Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. FMR LLC raised its holdings in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the last quarter. Point72 Asset Management L.P. lifted its position in Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in Affimed during the 3rd quarter valued at about $44,000. 30.82% of the stock is owned by institutional investors and hedge funds.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.